DOXYCYCLINE HYCLATE

Post-LOE

doxycycline hyclate

Hikma

ANDAORALTABLET

Approved

Jul 2003

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DOXYCYCLINE HYCLATE (doxycycline hyclate) by Hikma is mechanism of action doxycycline inhibits bacterial protein synthesis by binding to the 30s ribosomal subunit. Approved for the following infections: • rocky mountain spotted fever, typhus fever, the typhus group and 11 more indications. First approved in 2003.

Drug data last refreshed 18h ago

Mechanism of Action

Mechanism of Action Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. Resistance Cross resistance with other tetracyclines is common. Antimicrobial…

Indications (14)

Worked on DOXYCYCLINE HYCLATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (2)

NCT01087476Phase 2Unknown

Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate

Started May 2010

164 enrolled

Mucositis

NCT00688064Phase 3Completed

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

Started Aug 2008

459 enrolled

Severe Acne Vulgaris